De Vivo, D.C., Bertini, E., Swoboda, K.J., Hwu, W.L., Crawford, T.O., Finkel, R.S., et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 Nurture study. Neuromuscul Disord 29:11 (2019), 842–856.
Dangouloff, T., Burghes, A., Tizzano, E.F., Servais, L., NBS SMA Study Group. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord 30:1 (2020), 93–103.
Aragon-Gawinska, K., Seferian, A.M., Daron, A., Gargaun, E., Vuillerot, C., Cances, C., et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology 91:14 (2018), e1312–e1318.
Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., et al. Single-Dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:18 (2017), 1713–1722.
Dyer, O., Health ministers condemn Novartis lottery for Zolgensma, the world's most expensive drug. BMJ, 368, 2020, m580.
